eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
2/2004
vol. 8
 
Share:
Share:
abstract:

New preparations of hematopoietic growth factors

Anna Świeboda-Sadlej

Współcz Onkol (2004) vol. 8; 2 (96–100)
Online publish date: 2004/03/15
View full text Get citation
 
Cancer chemotherapy is associated with a high risk of complications due to neutropenia and thrombocytopenia. Over the past decade, several new preparations of hematopoietic growth factors have been developed. Some of them are reviewed in this paper. Pegfilgrastim (Neulasta, Amgen) is a novel pegylated form of filgrastim. Pegfilgrastim has a longer half-life than filgrastim, which allows for once-per-chemotherapy cycle frequency of administration and improves the patient’s quality of life. Its safety profile and tolerability are similar to those of filgrastim. Currently, rhIL-11 (Neulasta, Amgen) is the only cytokine licensed in the USA for treatment of chemotherapy-induced thrombocytopenia. rhIL-11 reduces the duration of thrombocytopenia and the need for platelet transfusions. c-MPL ligands such as recombinant human thrombopoietin (rhTpo) and pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) offer important promise for the treatment of thrombocytopenia. However, the development of neutralizing antibodies and clinically significant thrombocytopenia in some patients and normal donors is responsible for the delay in their commercial availability. Other hematopoietic growth factors, such as Steel factor (SLF), a fusion protein of Tpo and IL-3 and peptides that are hematopoietic growth factor mimetics presently evaluated for their clinical use are also mentioned in this review.
keywords:

hematopoietic growth factors, pegfilgrastim, rhIL-11, thrombopoietin, stem cell factor

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.